Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs

International Journal of Pharmaceutical Investigation

Volumn 5, Issue 4, 2015, Pages 182-191

  Khan, Saba ^a   Baboota, Sanjula ^a   Ali, Javed ^a   Khan, Sana ^a   Narang, Ramandeep Singh ^b   Narang, Jasjeet Kaur ^c  

^a HAMDARD UNIVERSITY   (India)

^b SGRD Dental College   (India)

^c KHALSA COLLEGE   (India)

Author keywords

Bioavailability; Cytochrome P450; Drug loading; In vivo performance; Lipid based formulations; Lipophilic; Nanostructured lipid carriers; P glycoprotein efflux; Solid lipid nanoparticles

Indexed keywords

BIOMATERIAL; CARRIER PROTEIN; CHYLOMICRON; CYTOCHROME P450; EMULSIFYING AGENT; ETOPOSIDE; FATTY ACID; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN; NANOMATERIAL; SAQUINAVIR; SIMVASTATIN; TAMOXIFEN; VINPOCETINE;

BILE SECRETION; CRYSTALLIZATION; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISPOSITION; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; EFFUSION; EMULSION; ENZYMATIC DEGRADATION; HYDROPHILICITY; LIPOPHILICITY; LOAD CARRYING CAPACITY; MICROEMULSION; PRIORITY JOURNAL; REVIEW; SOLUBILIZATION;

EID: 84976577618     PISSN: 2230973X     EISSN: 22309713     Source Type: Journal    
DOI: 10.4103/2230-973X.167661     Document Type: Review

References (72)

1. Desai P, Date A, Patravale B. Overcoming poor oral bioavailability using nanoparticle formulations-opportunities and limitations. Drug Discov Today Technol 2012;9:87-95.
2. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004;58:173-82.
3. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 2004;278:119-31.
4. Wandel C, Kim RB, Stein CM. Inactive excipients such as Cremophor can affect in vivo drug disposition. Clin Pharmacol Ther 2003;73:394-6.
5. Charman W. Lipid vehicle and formulation effects on intestinal lymphatic drug transport. In: Charman WN, Stella VJ, editors. Lymphatic Transport of Drugs. Boca Raton: CRC Press; 1992. p. 113-79.
6. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20.
7. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999;186:119-25.
8. Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 1996;140:111.
9. Thomson AB, Schoeller C, Keelan M, Smith L, Clandinin MT. Lipid absorption: Passing through the unstirred layers, brush-border membrane, and beyond. Can J Physiol Pharmacol 1993;71:531-55.
10. Read NW, Barber DC, Levin RJ, Holdsworth CD. Unstirred layer and kinetics of electrogenic glucose absorption in the human jejunum in situ. Gut 1977;18:865-76.
11. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998;87:1322-30.
12. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 2001;46:89-102.
13. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996;6:610-7.
14. Seelig A, Blatter XL, Wohnsland F. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison. Int J Clin Pharmacol Ther 2000;38:111-21.
15. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002;300:1036-45.
16. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: Biochemical aspects. Adv Drug Deliv Rev 2001;50 Suppl 1:S3.
17. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004;277:3-9.
18. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6:231-48.
19. Müller RH, Runge SA, Ravelli V, Thünemann AF, Mehnert W, Souto EB. Cyclosporine-loaded solid lipid nanoparticles (SLN): Drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm 2008;68:535-44.
20. Narang AS, Delmarre D, Gao D. Stable drug encapsulation in micelles and microemulsions. Int J Pharm 2007;345:9-25.
21. Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release 2008;129:1-10.
22. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.
23. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242:121-8.
24. Bunjes H, Westesen K, Koch M. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 1996;129:159-73.
25. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008;34:1394-405.
26. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine 2007;2:289-300.
27. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007;59:478-90.
28. Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007;59:522-30.
29. Uner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): Their benefits as colloidal drug carrier systems. Pharmazie 2006;61:375-86.
30. Zhuang CY, Li N, Wang M, Zhang XN, Pan WS, Peng JJ, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 2010;394:179-85.
31. zur Mühlen A, zur Mühlen E, Niehus H, Mehnert W. Atomic force microscopy studies of solid lipid nanoparticles. Pharm Res 1996;13:1411-6.
32. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces 2005;45:167-73.
33. Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: Comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 2011;415:232-43.
34. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: Transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11-23.
35. Lennernäs H. Intestinal drug absorption and bioavailability: Beyond involvement of single transport function. J Pharm Pharmacol 2003;55:429-33.
36. Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: In vitro/in vivo case studies. J Pharm Sci 2007;96:235-48.
37. O'Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility - the potential impact of lipid-based formulations. Adv Drug Deliv Rev 2008;60:617-24.
38. Tso P. Intestinal lipid absorption. In: Johnson LR, editor. Physiology of the Gastrointestinal Tract. New York: Raven Press; 1994. p. 1867-907.
39. Shete H, Patravale VS. Long chain lipid based tamoxifen NLC. Part I: Preformulation studies, formulation development and physicochemical characterization. Int J Pharm 2013;454:57383-92.
40. Zhang T, Chen J, Zhang Y, Shen Q, Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 2011;43:174-9.
41. Chen CC, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: Physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 2010;74:474-82.
42. Beloqui A, Solinís MÁ, Gascón AR, del Pozo-Rodríguez A, des Rieux A, Préat V. Mechanism of transport of saquinavir loaded nanostructured lipid carriers across the intestinal barrier. J Control Release 2013;166:115-23.
43. Shete H, Chatterjee S, De A, Patravale V. Long chain lipid based tamoxifen NLC. Part II: Pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int J Pharm 2013;454:584-92.
44. Yang X, Zhao L, Almasy L, Garamus VM, Zou A, Willumeit R, et al. Preparation and characterization of 4-dedimethylamino sancycline (CMT-3) loaded nanostructured lipid carrier (CMT-3/NLC) formulations. Int J Pharm 2013;450:225-34.
45. Westergaard H, Dietschy JM. The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into the intestinal mucosal cell. J Clin Invest 1976;58:97-108.
46. Dulfer WJ, Groten JP, Govers HA. Effect of fatty acids and the aqueous diffusion barrier on the uptake and transport of polychlorinated biphenyls in Caco-2 cells. J Lipid Res 1996;37:950-61.
47. Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 2004;284:109-22.
48. Ahuja N, Katare OP, Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur J Pharm Biopharm 2007;65:26-38.
49. Batrakova EV, Li S, Li Y, Alakhov VY, Kabanov AV. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 2004;21:2226-33.
50. Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs 2004;22:219-29.
51. Chen MC, Wang JL, Tzen JT. Elevating bioavailability of cyclosporine a via encapsulation in artificial oil bodies stabilized by caleosin. Biotechnol Prog 2005;21:1297-301.
52. Komarov PG, Shtil AA, Buckingham LE, Balasubramanian M, Piraner O, Emanuele RM, et al. Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function. Int J Cancer 1996;68:245-50.
53. Lo YL, Huang JD. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol 2000;59:665-72.
54. Ruetz S, Gros P. Enhancement of Mdr2-mediated phosphatidylcholine translocation by the bile salt taurocholate. Implications for hepatic bile formation. J Biol Chem 1995;270:25388-95.
55. Batrakova E, Lee S, Li S, Venne A, Alakhov V, Kabanov A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm Res 1999;16:1373-9.
56. Miller DW, Batrakova EV, Kabanov AV. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm Res 1999;16:396-401.
57. Zordan-Nudo T, Ling V, Liu Z, Georges E. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res 1993;53:5994-6000.
58. Batrakova EV, Li S, Miller DW, Kabanov AV. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res 1999;16:1366-72.
59. Rege BD, Kao JP, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002;16:237-46.
60. Romsicki Y, Sharom FJ. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 1999;38:6887-96.
61. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, et al. Reversal of multidrug resistance by surfactants. Br J Cancer 1992;66:62-8.
62. Dahan A, Hoffman A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm Res 2006;23:2165-74.
63. Caliph SM, Charman WN, Porter CJ. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 2000;89:1073-84.
64. O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 2002;15:405-15.
65. Porter CJ, Charman WN. Intestinal lymphatic drug transport: An update. Adv Drug Deliv Rev 2001;50:61-80.
66. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update. Adv Drug Deliv Rev 2008;60:702-16.
67. Cense HA, van Eijck CH, Tilanus HW. New insights in the lymphatic spread of oesophageal cancer and its implications for the extent of surgical resection. Best Pract Res Clin Gastroenterol 2006;20:893-906.
68. Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M, Patel HR. The metastatic cascade in prostate cancer. Surg Oncol 2006;15:117-28.
69. Dabholkar RD, Sawant RM, Mongayt DA, Devarajan PV, Torchilin VP. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: Some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm 2006;315:148-57.
70. Zhang C, Peng F, Liu W, Wan J, Wan C, Xu H, et al. Nanostructured lipid carriers as a novel oral delivery system for triptolide: Induced changes in pharmacokinetics profile associated with reduced toxicity in male rats. Int J Nanomedicine 2014;9:1049-63.
71. Rahman HS, Rasedee A, Othman HH, Chartrand MS, Namvar F, Yeap SK, et al. Acute toxicity study of zerumbone-loaded nanostructured lipid carrier on BALB/c mice model. Biomed Res Int 2014;2014:563930.
72. Sharma S, Ali A, Ali J, Sahni JK, Baboota S. Rutin: Therapeutic potential and recent advances in drug delivery. Expert Opin Investig Drugs 2013;22:1063-79.